

SECTION-1: Identification of the substance / mixture and the company / undertaking

Catalogue Number	CS-T-62623
Product Name	Ubrogepant
CAS No.	1374248-77-7
Category	API
Synonyms	Not available
Brand	Clearsynth Labs Ltd.
Identified uses	Laboratory Chemicals
Uses advised against	Not available
Company	Clearsynth Labs Ltd. Mumbai, India
Emergency Phone #	+91-22-245045900
REACH No.	Not available

SECTION 2: Hazards identification

Disclaimer: This is sample MSDS. Please email sales@clearsynth.com for more details.

2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

2.2 Label Elements

Signal Word: Not available

Not available

Hazard Statement(s)

Code	Statement
Not available	Not available

Precautionary Statement(s)

Code	Statement
Not available	Not available

SECTION 3: Composition / information on ingredients

3.1 Substance

Component : Ubrogapant
CAS Number : 1374248-77-7
Molecular Formula : Not available
Molecular Weight : Not available
Parent Chemical : Ubrogapant
Synonyms : Not available
Concentration : Not available

SECTION 4: First aid measures

SECTION 4: First-aid measures

4.1 Description of first aid measures

General advice: Seek medical attention if symptoms occur or persist. Show this SDS to the physician.

Inhalation: Move person to fresh air. If breathing is difficult, seek medical attention.

Skin contact: Wash with plenty of soap and water. Remove contaminated clothing and wash before reuse. Seek medical attention if irritation develops.

Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention if irritation persists.

Ingestion: Rinse mouth. Do not induce vomiting unless directed by medical personnel. Seek medical attention.

4.2 Most important symptoms/effects, acute and delayed

Not available.

4.3 Indication of immediate medical attention and special treatment needed

Treat symptomatically. No data available.

SECTION 5: Firefighting measures

SECTION 5: Fire-fighting measures

5.1 Suitable extinguishing media

Use extinguishing measures appropriate to local circumstances and the surrounding environment (e.g., water spray, dry chemical, foam, carbon dioxide).

5.2 Special hazards arising from the substance or mixture

No data available. Combustion may produce carbon oxides, nitrogen oxides, and other irritating/toxic fumes.

5.3 Advice for firefighters

Wear self-contained breathing apparatus (SCBA) and full protective gear. Avoid inhalation of combustion products. Use water spray to cool unopened containers exposed to heat.

SECTION 6: Accidental release measures

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Avoid breathing dust. Avoid contact with skin and eyes. Use appropriate personal protective equipment. Ensure adequate ventilation.

6.2 Environmental precautions

Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Do not allow to enter drains/surface waters/groundwater.

6.3 Methods and material for containment and cleaning up

Contain spill. Collect spilled material using methods that minimize dust generation (e.g., damp wipe, HEPA-filtered vacuum). Place in a suitable, closed container for disposal. Clean contaminated area.

6.4 Reference to other sections

See Section 8 for personal protective equipment and Section 13 for disposal considerations.

SECTION-7: Handling and storage

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Handle in accordance with good industrial hygiene and safety practice. Avoid formation of dust and aerosols. Avoid breathing dust. Avoid contact with skin, eyes, and clothing. Use with adequate ventilation.

7.2 Conditions for safe storage, including any incompatibilities

Store in a tightly closed container in a cool, dry, well-ventilated place. Protect from moisture. Keep away from incompatible materials.

Incompatible materials: Not available.

7.3 Specific end use(s)

API / laboratory and research use. Not for food, drug, or household use.

SECTION 8: Exposure controls / personal protection

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits: Not available.

Biological limit values: Not available.

8.2 Exposure controls

Engineering controls: Provide appropriate exhaust ventilation and/or process enclosure to control airborne levels.

Use local exhaust where dust may be generated.

Personal protective equipment (PPE):

- Eye/face protection: Safety glasses with side shields or chemical splash goggles.
- Skin protection: Protective gloves (material not available). Wear protective clothing as appropriate.
- Respiratory protection: If ventilation is inadequate or dust is generated, use a NIOSH/EN-approved particulate respirator as appropriate.
- Hygiene measures: Wash hands after handling. Remove contaminated clothing and wash before reuse. Do not eat, drink, or smoke when using this product.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

SECTION 10: Stability and reactivity

SECTION 10: Stability and reactivity

10.1 Reactivity

No data available.

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No data available.

10.4 Conditions to avoid

Avoid dust formation. Avoid heat, sparks, open flames, and other ignition sources. Avoid moisture (if applicable).

10.5 Incompatible materials

Not available.

10.6 Hazardous decomposition products

No data available. Thermal decomposition/combustion may produce carbon oxides, nitrogen oxides, and other irritating/toxic fumes.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

- Acute toxicity: In preregistration controlled trials of ubrogepant in several thousand patients, mild-to-moderate serum aminotransferase elevations arose in a small percentage of patients (1% to 2%) and overall rates were not different from those in placebo recipients. In the controlled trials and subsequently with general use, there have been no reports of clinically apparent liver injury attributed to ubrogepant. In contrast, telcagepant, the initial oral CGRP receptor antagonist evaluated as therapy for migraine headaches, was abandoned during development because of several instances of clinically apparent liver injury in recipients that was characterized by marked elevations in serum aminotransferase levels and symptoms of fatigue, nausea and abdominal discomfort arising within 2 to 4 weeks of starting therapy which rapidly resolved with prompt stopping of therapy. Similar episodes have not been reported with ubrogepant. Likelihood score: E (unlikely cause of clinically apparent acute liver injury).

- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.
- Germ cell mutagenicity: No data available.
- Carcinogenicity: No data available.
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: No data available.
- Aspiration hazard: No data available.

Likely routes of exposure

- No data available.

Symptoms related to the physical, chemical and toxicological characteristics

- In preregistration controlled trials of ubrogepant in several thousand patients, mild-to-moderate serum aminotransferase elevations arose in a small percentage of patients (1% to 2%) and overall rates were not different from those in placebo recipients. In the controlled trials and subsequently with general use, there have been no reports of clinically apparent liver injury attributed to ubrogepant. In contrast, telcagepant, the initial oral CGRP receptor antagonist evaluated as therapy for migraine headaches, was abandoned during development because of several instances of clinically apparent liver injury in recipients that was characterized by marked elevations in serum aminotransferase levels and symptoms of fatigue, nausea and abdominal discomfort arising within 2 to 4 weeks of starting therapy which rapidly resolved with prompt stopping of therapy. Similar episodes have not been reported with ubrogepant. Likelihood score: E (unlikely cause of clinically apparent acute liver injury).

SECTION 12: Ecological information

SECTION 12: Ecological information

12.1 Toxicity

Not available.

12.2 Persistence and degradability

Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Not available.

12.5 Results of PBT and vPvB assessment

Not available.

12.6 Endocrine disrupting properties

Not available.

12.7 Other adverse effects

Not available.

SECTION 13: Disposal considerations

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Dispose of contents/container in accordance with local/regional/national/international regulations.

Do not discharge to drains.

Recommended disposal: Incineration or disposal via a licensed chemical waste contractor, as appropriate.

Contaminated packaging: Dispose of as unused product.

SECTION 14: Transport information

SECTION 14: Transport information

14.1 UN number

Not available.

14.2 UN proper shipping name

Not available.

14.3 Transport hazard class(es)

Not available.

14.4 Packing group

Not available.

14.5 Environmental hazards

Not available.

14.6 Special precautions for user

Not available.

14.7 Maritime transport in bulk according to IMO instruments

Not available.

SECTION 15: Regulatory information

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not available.

15.2 Chemical safety assessment

Not available.

SECTION 16: Other information

SECTION 16: Other information

Product name: Ubrogapant

Catalog no.: CS-T-62623

CAS no.: 1374248-77-7

Supplier: Clearsynth Labs Ltd., Mumbai, India

Emergency phone: +91-22-245045900

Disclaimer: The information provided is believed to be accurate based on available data; however, it is provided without warranty. Users are responsible for determining suitability for their particular application and for complying with applicable laws and regulations.

Revision date: Not available.

DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.